The impact of fatigue in rheumatoid arthritis and the challenges of its assessment

Eduardo J. F. Santos 1,2,3, Catia Duarte 1,4, José A. P. da Silva 1,4 and Ricardo J. O. Ferreira 1,3

Abstract

Fatigue is one of the most important symptoms for patients with RA, and imposes a great burden on patients’ lives, being associated with significantly reduced health-related quality of life. Although being recognized by the rheumatology community as a major gap in the current management of the disease, fatigue has not been easy to measure and conceptualize. Part of the problem seems to reside in the multidimensional causality of this phenomenon, which may warrant dedicated measures and interventions. Although there are several instruments available to measure it, no consensus has yet been reached to recommend a ‘gold-standard’. This review aims at synthesizing the role of fatigue in the global impact of RA; describing validated instruments and their psychometric properties as measures of fatigue among patients with RA; and finally proposing a clinically meaningful, valid and feasible process to measure fatigue in clinical practice.

Key words: arthritis, rheumatoid, fatigue, psychometrics, outcome assessment (health care)

Rheumatology key messages

- Fatigue is a significant component of the global impact of rheumatoid arthritis (RA).
- Clinicians and researchers should only use valid instruments to measure fatigue in patients with RA.
- Clinicians could screen fatigue in RA with single-item instruments, complemented with multidimensional ones if needed.

Introduction

Fatigue is a common and persistent problem in musculo-skeletal and rheumatic diseases, including RA [1, 2]. It affects around 40–80% of these patients [3, 4], being defined as severe in about half of the cases [3, 5–7], and has negative impact upon health-related quality of life [8]. Fatigue is experienced as being overwhelming, unpredictable, extreme, not restored by sleep, multidimensional and part of a vicious circle in which fatigue feeds and fosters itself [9, 10]. Coherently, fatigue is considered as one of the most important disease outcomes by patients [8, 11, 12]. It has received increased attention over the past decade and has been recommended by the Outcome Measures in Rheumatology Clinical Trials (OMERACT) group as an important outcome domain that should be assessed in all RA studies, alongside the core set [13].

Despite having been historically considered an extra-articular manifestation of RA, related to disease activity, recent findings support a multifactorial aetiology for fatigue, involving an array of co-morbid factors, such as disability, psychological well-being, social support and ‘overall evaluation of health’ [14].

The measurement of fatigue in RA entails several challenges due to its subjective nature and close relationship with cognitive and emotional dimensions [15]. Characteristics of the experience and consequences of fatigue are likely to be unique in RA patients, which imposes the need for specific assessment instruments [13]. Generic instruments may, as an example, contain items that in RA would capture the restrictions imposed by inflammation or disability, rather than by fatigue itself, leading to unreliable or misleading results [15]. Previous
reviews confirmed that the majority of the numerous instruments used to assess fatigue in RA are well validated psychometrically, but lack evidence of their validity in the specific clinical context of RA [16, 17]. This may help explain why no consensus has yet been reached on how to measure it in this disease.

For the purpose of this review, and to further evolve this area, we chose to analyse only the instruments with reasonable evidence of validation for measuring fatigue in RA, diagnosed with established criteria. The aims of this review are: (i) to synthesize the role of fatigue in the global impact of RA, (ii) to describe validated instruments and their psychometric properties as measures of fatigue in patients with RA, and (iii) to propose a clinically meaningful and valid process to measure fatigue in clinical practice.

**Importance of fatigue in the global impact of RA**

Fatigue has a significant negative impact on patients’ ability to perform daily self-care and socially relevant tasks [18–20], to the detriment of physical and mental or emotional well-being and personal satisfaction [14, 21]. As a consequence of fatigue, patients experience higher levels of interpersonal stress, including with friends and family members [20]. Fatigue has been found to account for 30–44% of role limitations, 52–57% of physical and social functioning problems, 64% of mental health symptoms, and 51% of the general perception of health worsening in RA [21].

Work disability is among the most important consequences of fatigue in RA. In fact, patients have identified this symptom as the principal barrier to employment and reduced productivity [22, 23] and this has been extensively demonstrated by research. In a longitudinal study, the likelihood of absenteeism at 6 and 12 months was significantly higher in those describing more fatigue at baseline (odds ratio (OR) 1.23; 95% CI: 1.02, 1.49). Fatigue was also associated with activity impairment (OR 1.52; 95% CI: 0.79, 2.26) and work productivity loss (OR 4.16; 95% CI: 2.47, 5.85) [22]. Fatigue was also associated with more physicians’ consultations and more referrals to therapists over time [24]. This indicates that fatigue is probably associated with considerable additional societal costs in RA although, to our knowledge, this has not been the object of specific publications.

Altogether, these findings can justify why fatigue is considered an important cause of ‘difficult to treat’ RA patients [25], making the management of RA more challenging and causing greater health care utilization.

Fatigue significantly affects the assessment of disease activity: it has been identified as the main driver of patient self-assessment of global impact of the disease (patient global assessment). This is true even in patients in disease remission, i.e. with good control of the inflammatory process [26, 27]. It has been shown that when fatigue persists, patients will not perceive the achievement of favourable clinical outcomes [28]. Patient global assessment has a significant weight in current disease activity indices used to guide treatment decisions [27, 29, 30], thus conveying an indirect impact of fatigue in heightened medication cost and risk of overtreatment.

**Instruments and their psychometric properties**

The information above underlines the need to accurately assess fatigue both in research and in clinical settings. Clearly, the choice of the instrument to measure fatigue is an essential step and the challenge this represents should not be underestimated. Although several instruments are available for this purpose, two main problems arise. The first is their limited validation. Frequently, publications using these instruments do not include references of validation studies, or do not fully describe the instrument. Therefore, it cannot be ruled out that significant variations in wording of the questions, in time reference (e.g. last week, last month) and even in the number of items may have occurred in different instances of use of the same instrument. This is quite clear with the single-item visual analogue scales, for which several versions were identified [16]. The second problem relates to the use in RA of instruments developed and validated for application in patients with other rheumatic diseases, other diseases, such as cancer [16, 31], or in the general population. The use of such non-specific instruments may entail important issues, namely ‘contamination bias’, whereby some items may distort the assessment of fatigue by influence of other distinct outcomes in RA: physical function impairment or joints’ inflammatory activity. The purpose of fatigue assessment should drive the selection of the instrument and sometimes both RA-specific and non-specific instruments should be used. Whatever the case, clinicians and researchers should consider using only instruments with adequate validation [16, 17], i.e. instruments that have been proven to measure exactly what is purported (validity) and that provide consistent results at different time points (reliability) or are able to detect relevant changes over time (sensitivity to change) [32].

To select instruments for this narrative literature review we used two criteria: (i) being the most used by clinicians and researchers in patients with RA, according to published reports; and (ii) having reasonable evidence of validation regarding acceptability, validity, reliability and sensitivity to change in RA. Searches were limited to PUBMED and CINAHL, in the English language and without restriction of dates. The search strategy included the following descriptors: fatigue, tiredness, scale, questionnaire, checklist, inventory and psychometrics. One researcher (E.S.) reviewed all abstracts, and then full articles were reviewed to identify the fatigue instrument used and to extract information on their psychometric properties, appraised by all researchers. We have thus identified 12 instruments [16, 33–47], which are presented in Tables 1 and 2. Then, a score was attributed to the psychometric properties of each instrument according to the strength of the available evidence based on its validation studies (strong/good evidence, moderate evidence,
Based on their characteristics and psychometric properties, all the selected instruments may be considered adequate to measure RA fatigue, depending on the clinical setting and the objectives. However, further studies and cooperative work are required to address specific needs such as the elimination of ‘contamination bias’, the consensual adoption of a ‘gold standard’, the definition of clinically relevant and validated cut-offs to assist in patient care management, and the development and validation of a standardized single-item assessment tool.

The constitution of a task-force with the different stakeholders may be the solution to achieving much-needed progress. A complete systematic review of outcome measurement instruments based on the current guidelines is dearly needed and the use of the COSMIN methodology (https://www.cosmin.nl/) is imperative. Furthermore, an update of previous reviews is needed as they considered low/limited evidence, not applicable) (Table 2). For more details on the psychometric properties and full description of the instruments, readers are advised to appraise their validation studies (last column of Table 2) and/or previous reviews [16, 17].

### Table 1 Summary of the characteristics of the selected fatigue assessment instruments

| Instrument | Information/strengths | Specifically designed for RA | Free to use | Number of items | Time to self-report | Higher score means |
|------------|-----------------------|------------------------------|-------------|-----------------|--------------------|--------------------|
| BRAF MDQ   | Developed with RA patients. Measures multiple dimensions of fatigue | Yes | Yes | 20 | 4-5 min | Higher fatigue |
| BRAF NRS   | Developed with RA patients. Measures severity, impact and coping | Yes | Yes | 3 | 1 min | High severity and effect = higher fatigue; high coping = better fatigue |
| CFQ        | Measures severity and uses different subscales | No | Yes | 11 | 2-3 min | Higher fatigue |
| CIS20R and CIS8R | Used in several long-term conditions | No | Yes | 20 or 8 | 4-5 min | Higher fatigue |
| FSS        | Recommended scale for systemic lupus erythematosus but also used in other rheumatic conditions | No | Yes | 9 | 2-3 min | Higher fatigue |
| FACIT-F    | Used in several rheumatic conditions and in other chronic illnesses | No | Yes, except for commercial studies | 13 | 3-4 min | Better |
| MAF        | Specific for RA but used in other chronic illnesses | Yes | Yes, except for commercial studies | 15 | 5-8 min | Higher fatigue |
| MFI        | Used in several rheumatic conditions and in other chronic illnesses | No | Yes, except for commercial studies | 20 | 4-5 min | Higher fatigue |
| SF-36 VT   | Measures energy and fatigue in general and clinical populations. Widely used | No | No | 4 | 1 min | Better |
| VAS        | Feasible to measure a variety of fatigue constructs. Widely used | No | Yes | Variable | 1 min | Higher fatigue |
| RAID-F     | VAS developed with RA patients | Yes | Yes | 1 | 1 min | Higher fatigue |
| POMS       | Although designed to measure mood, the fatigue/inertia scale has been used to assess fatigue experienced by RA patients | No | Yes, except for commercial studies | 7 | 2-3 min | Higher fatigue |

BRAF MDQ: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire; BRAF NRS: Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales for severity, effect and coping; CFQ: Chalder Fatigue Questionnaire; CIS20R and CIS8R: Checklist Individual Strength; FACIT-F: Functional Assessment Chronic Illness Therapy (Fatigue); FSS: Fatigue Severity Scale; MAF: Multi-Dimensional Assessment of Fatigue; MFI: Multi-Dimensional Fatigue Inventory; POMS: Profile of Mood States; RAID-F: Rheumatoid Arthritis Impact of Disease Fatigue Subscale; SF-36 VT: Short Form 36 Vitality Subscale; VAS: Visual Analogue Scales.
publications until 2004 [16] or not stated (2011 at best) [17], and further psychometric studies have been published (e.g. on BRAF and RAID) or new instruments developed since these reviews were published.

**Putting the evidence together: a preliminary proposal to measure fatigue in practice**

Although fatigue was defined as a core outcome for clinical trials by the ACR/EULAR [48] and was the topic of a study interest group of OMERACT, these leading organizations did not specify/recommend a gold-standard instrument to assess fatigue. The diversity of instruments and their relative advantages and limitations have been the subject of discussion by clinicians and researchers [49].

The arguments for using disease-specific vs generic instruments, or multi-item/multidimensional vs single-item instruments are still open [50]. One large study suggested that scoring different components of fatigue does not appear to add relevant information to that provided by a single-item instrument [51]. However, this may depend on the intended use of the information (e.g. a self-management intervention or a medication change). Also, a set of qualitative studies have suggested that the RA-specific, multi-dimensional instruments are needed to fully and precisely identify fatigue specific to RA [33, 52, 53].

From the patient’s perspective there are three essential aspects of impact of disease that require assessment (the so-called ‘Impact Triad’): the severity of an outcome (e.g. fatigue), its importance to the patient (i.e. in comparison with the ‘usual’ status or with other symptoms), and patient ability to self-manage/cope with that perceived severity. In other words, it is important to consider how symptom severity and self-management may influence patient priorities or the importance of outcomes for an individual person [54]. The development of the BRAF-NRS considered this triad, and this was the instrument

| TABLE 2 Summary of psychometric properties of the selected fatigue assessment instruments |
|-----------------------------------|---------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Instrument                        | Acceptability                  | Internal consistency | Test-retest   | Content validity | Construct validity | Criterion validity | Ability to detect change | Validation studies |
|----------------------------------|--------------------------------|---------------------|---------------|------------------|--------------------|-------------------|----------------------|------------------|
| BRAF MDQ                         | Strong                         | Strong              | Strong        | Strong           | Strong             | Strong            | Moderate             | Good             | [33–36]         |
| BRAF NRS                         | Strong                         | Strong              | NA            | Strong           | Strong             | Strong, moderate   | Good                 | Good             | [33–36]         |
| CFQ                              | Low                            | Strong              | Strong        | Moderate         | Moderate           | Moderate          | Good                 | [37, 38]         |
| CFQ                              | Low                            | Strong              | Strong        | Moderate         | Moderate           | Strong            | Good                 | [39]             |
| FSS                              | Moderate                      | Strong              | Strong        | Strong           | Moderate           | Strong            | Good                 | [40]             |
| FACIT-F                          | Moderate                      | Strong              | Strong        | Moderate         | Strong             | Strong            | Good                 | [41]             |
| MAF                              | Moderate                      | Strong              | Strong        | Moderate         | Strong             | Moderate          | Strong               | Good             | [42]             |
| MAF                              | Moderate                      | Strong              | Strong        | Moderate and     | Moderate           | Strong            | Good                 | [43]             |
| SF-36 VT                         | Strong                         | Strong              | Very weak     | Moderate         | Strong             | Moderate to strong | Good                 | [44]             |
| VAS                              | Moderate                      | NA                  | Strong        | No standard      | Strong             | Moderate to strong | Good                 | [16]             |
| RAID-F                           | Strong                         | NA                  | Strong        | Moderate to      | Strong             | Strong            | Good                 | [45, 46]         |
| POMS                             | Moderate                      | Strong              | Moderate      | Low              | Moderate and       | Moderate          | —                    | [47]             |

*Based on the ease of reading and understanding, levels of missing data reported and presence of floor or ceiling effects.

BRAF MDQ: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire; BRAF NRS: Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales for severity, effect and coping; CFQ: Chalder Fatigue Questionnaire; CIS20R and CIS8R: Checklist Individual Strength; FACIT-F: Functional Assessment Chronic Illness Therapy (Fatigue); FSS: Fatigue Severity Scale; MAF: Multi-Dimensional Assessment of Fatigue; MFI: Multi-Dimensional Fatigue Inventory; NA: not applicable; POMS: Profile of Mood States; RAID-F: Rheumatoid Arthritis Impact of Disease Fatigue Subscale; SF-36 VT: Short Form 36 Vitality Subscale; VAS: Visual Analogue Scales.
Impact and assessment of fatigue in RA

used in a recent randomized controlled trial, which demonstrated that cognitive behavioural intervention had short and long term efficacy on the BRAF-NRS impact but not a similar efficacy in coping with (only in the longer term) or in the severity of fatigue [55].

In the absence of formal recommendations, clinicians and researchers should consider whether their needs are best served by a single-item instrument, a multi-item instrument that explores broader fatigue issues to create a global score, or a multidimensional instrument that produces subscale scores for a range of different domains of fatigue (e.g. cognitive and physical fatigue) [17]. This open choice has, however, the drawback of limiting comparison across studies. A strategic option for clinical practice may be to use a single-item instrument as a screening tool (e.g. BRAF NRS, RAID-F), which would be supplemented by additional multidimensional assessments, if significant levels of fatigue are identified by screening. This will be particularly useful when the aims are to explore fatigue causality or the efficacy of interventions [17].

Given the multifactorial nature of fatigue, it may be wise to measure other domains of significant impact for patients. In fact, previous studies associated fatigue with specific domains of disease impact (e.g. pain, functional disability and sleep disturbances [12, 56]), suggesting that efficient interventions in these domains may contribute to significant reductions of fatigue levels. In our opinion, the most suitable instrument for this purpose is, currently, the Rheumatoid Arthritis Impact of Disease Score (RAID) [45, 46] which considers seven different domains of impact: pain, functional disability, fatigue, emotional well-being, physical well-being, sleep and coping. RAID was developed and validated as a combined index of overall impact, resulting from the consideration of the seven dimensions (original formulation). The NRS used to assess individual domains of disease impact in RAID are valid, feasible, reliable and sensitive to change in patients with RA [46, 57, 58]. Using the seven scores separately (RAID-7i) offers a feasible tool to analyse impact of disease and to design and monitor individually tailored interventions, targeting the domains of concern, and thus indirectly improving fatigue.

Conclusions

Fatigue is, undisputedly, an outcome of outstanding importance for patients with RA and, thus, for the conceptualization and achievement of treatment targets.

It should be regularly measured in both research and clinical practice. A number of validated instruments are available to this purpose but there is no consensus definition of gold standard.

The use of a single item tool, followed by multidimensional instruments as appropriate, seems to be a suitable proposal for clinical practice.

Acknowledgements

We wish to thank to Professor Emma Dures (University of the West of England, Bristol) for critically revising the manuscript for its intellectual content. All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published.

Funding: This supplement is supported by a grant from Gilead Sciences, Inc.

Disclosure statement: The authors have declared no conflicts of interest.

References

1 van Steenbergen HW, Tsonaka R, Huizinga TWJ, Boonen A, van der Helm-van Mil A. Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study. RMD Open 2015;1:e000041.
2 Walter MJM, Kuijper TM, Hazes JM, Weel AE, Luime JJ. Fatigue in early, intensively treated and tight-controlled rheumatoid arthritis patients is frequent and persistent: a prospective study. Rheumatol Int 2018;38:1643–50.
3 Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford) 2006;45:885–9.
4 Hewlett S, Chalder T, Choy E et al. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology 2011;50:1004.
5 Overman CL, Kool MB, Da Silva JA, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol 2016;35:409–15.
6 Repping-Wuts H, Fransen J, van Achterberg T, Bleijenberg G, van Riel P. Persistent severe fatigue in patients with rheumatoid arthritis. J Clin Nurs 2007;16:377–83.
7 Druce KL, Bhattacharya Y, Jones GT, Macfarlane GJ, Basu N. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 2016;55:1786–90.
8 Matcham F, Ali S, Hotopf M, Chalder T. Psychological correlates of fatigue in rheumatoid arthritis: a systematic review. Clin Psychol Rev 2015;39:16–29.
9 Feldthuusen C, Bjork M, Forsblad-d’Elia H, Mannerkorpi K. Perception, consequences, communication, and strategies for handling fatigue in persons with rheumatoid arthritis of working age—a focus group study. Clin Rheumatol 2013;32:557–66.
10 Sharpe M. Cognitive behavior therapy for chronic fatigue syndrome: efficacy and implications. Am J Med 1998;105:104S–95.
11 Hewlett S, Carr M, Ryan S et al. Outcomes generated by patients with rheumatoid arthritis: how important are they? Musculoskeletal Care 2005;3:131–42.
12 Santos EJF, Duarte C, Ferreira RJO et al. Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach. Ann Rheum Dis 2018;77:1118–24.
13 Kirwan JR, Minnock P, Adebajo A et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174–7.
14 Suurmeijer TP, Waltz M, Mourm T et al. Quality of life profiles in the first years of rheumatoid arthritis: results from the EURIDISS longitudinal study. Arthritis Rheum 2001;45:111–21.

15 Hewlett S, Cockshott Z, Byron M et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697–702.

16 Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum 2007;57:429–39.

17 Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S263–86.

18 Franklin AL, Harrell TH. Impact of fatigue on psychological outcomes in adults living with rheumatoid arthritis. Nurs Res 2013;62:203–9.

19 Breedveld FC, Han C, Baia M et al. Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:52–5.

20 Nikolaus S, Bode C, Taal E, van de Laar MA. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2013;65:1128–46.

21 Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA. Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum 2004;51:578–85.

22 Druce KL, Aikman L, Dilleen M et al. Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients. Arthritis Res Ther 2018;20:96.

23 Gignac MA, Lacaille D, Beaton DE et al. Striking a balance: work-health-personal life conflict in women and men with arthritis and its association with work outcomes. J Occup Rehabil 2014;24:573–84.

24 Waltz M. The disease process and utilization of health services in rheumatoid arthritis: the relative contributions of various markers of disease severity in explaining consumption patterns. Arthritis Care Res 2000;13:74–98.

25 Roodenrijs NMT, de Hair MJH, van der Goes MC et al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis 2018;77:1705.

26 van Tuyil LH, Sadlonova M, Hewlett S et al. The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. Ann Rheum Dis 2017;76:855–61.

27 Ferreira RJO, Dougados M, Kirwan JR et al. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology (Oxford) 2017;56:1573–8.

28 Steunebrink LMM, Oude Voshaar MAH, Taal E et al. Determinants of perceived health nonimprovement in early rheumatoid arthritis patients with favorable treatment outcomes. Arthritis Care Res (Hoboken) 2018;70:510–5.

29 Ferreira RJO, Duarte C, Ndosi M et al. Suppressing inflammation in rheumatoid arthritis: does patient global assessment blur the target? A practice-based call for a paradigm change. Arthritis Care Res (Hoboken) 2018;70:368–78.

30 Ward MM, Guthrie LC, Dasgupta A. Direct and indirect determinants of the patient global assessment in rheumatoid arthritis: differences by level of disease activity. Arthritis Care Res (Hoboken) 2017;69:323–9.

31 Stebbings S, Treharne GJ. Fatigue in rheumatic disease: an overview. Int J Clin Rheumatol 2010;5:487–502.

32 Souza ACd, Alexandre NMC, Guirardello EB. Psychometric properties in instruments evaluation of reliability and validity. Epidemiol Serv Saude 2017;26:649–59.

33 Nicklin J, Cramp F, Kirwan J, Urban M, Hewlett S. Collaboration with patients in the design of patient-reported outcome measures: capturing the experience of fatigue in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:1552–8.

34 Nicklin J, Cramp F, Kirwan J et al. Measuring fatigue in rheumatoid arthritis: a cross-sectional study to evaluate the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional questionnaire, visual analog scales, and numerical rating scales. Arthritis Care Res (Hoboken) 2010;62:1559–68.

35 Hewlett S, Kirwan J, Bode C et al. The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries. Rheumatology (Oxford) 2018;57:300–8.

36 Dures EK, Hewlett SE, Cramp FA et al. Reliability and sensitivity to change of the Bristol Rheumatoid Arthritis Fatigue scales. Rheumatology (Oxford) 2013;52:1832–9.

37 Cella M, Chalder T. Measuring fatigue in clinical and community settings. J Psychosom Res 2010;69:17–22.

38 Chalder T, Berelowitz G, Pawlikowska T et al. Development of a fatigue scale. J Psychosom Res 1993;37:147–53.

39 Vercoulen JH, Swanink CM, Fennis JF et al. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994;38:383–92.

40 Krupp LB, LaRocca NG, Muir NJ, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121–3.

41 Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63–74.

42 Tack B. Dimensions and correlates of fatigue in older adults with rheumatoid arthritis. Dissertation, University of California, San Francisco, 1991.

43 Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric
qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315–25.
44 Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
45 Gossec L, Dougados M, Rincheval N et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009;68:1680–5.
46 Gossec L, Paternotte S, Aanerud GJ et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 2011;70:935–42.
47 McNair D, Lorr M, Droppleman L. Profile of mood states manual. New York: Multi-Health Systems Inc., 1992.
48 Aletaha D, Landewe R, Karonitsch T et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360–4.
49 Katz P. Fatigue in Rheumatoid Arthritis. Curr Rheumatol Rep 2017;19:25.
50 Oude Voshaar MA, Ten Klooster PM, Bode C et al. Assessment of fatigue in rheumatoid arthritis: a psychometric comparison of single-item, multiitem, and multidimensional measures. J Rheumatol 2015;42:413–20.
51 Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004;31:1896–902.
52 Nikolaus S, Bode C, Taal E, van de Laar M. Four different patterns of fatigue in rheumatoid arthritis patients: results of a Q-sort study. Rheumatology (Oxford) 2010;49:2191–9.
53 Nikolaus S, Bode C, Taal E, van de Laar M. Which dimensions of fatigue should be measured in patients with rheumatoid arthritis? A Delphi study. Musculoskelet Care 2012;10:13–7.
54 Sanderson TC, Hewlett SE, Flurey C et al. The impact triad (severity, importance, self-management) as a method of enhancing measurement of personal life impact of rheumatic diseases. J Rheumatol 2011;38:191–4.
55 Hewlett S, Almeida C, Ambler N et al. Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). Ann Rheum Dis 2019;78:465.
56 van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology (Oxford) 2010;49:1294–302.
57 Ferreira RJO, Gossec L, Duarte C et al. The Portuguese Rheumatoid Arthritis Impact of Disease (RAID) score and its measurement equivalence in three countries: validation study using Rasch Models. Qual Life Res 2018;27:2909–21.
58 Holtén K, Sexton J, Kvien TK, Aga A-B, Haavardsholm EA. Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC study. RMD Open 2018;4:e000754.